Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

Hypogonadism, Male Clinical Trial

Official title:

A 6 Month, Open Label, Ambulatory Blood Pressure Monitoring (ABPM) Extension Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04467697
• Other study ID #: MRS-TU-2019EXT
• Status: Completed
• Phase: Phase 3
• Start date: September 18, 2018
• Est. completion date: May 1, 2020

Study information

• Verified date: January 2021
• Source: Marius Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this six-month treatment extension study is

• to assess feasibility of a lower starting dose of SOV2012-F1 (daily dose of 400 mg [200 mg with breakfast meal and 200mg with dinner meal]) to titrate individual doses in order to further enhance drug administration.

• To examine the blood pressure (BP) effects of Marius's oral testosterone undecanoate formulation, SOV2012-F1, using 24-hour ambulatory blood pressure monitoring (ABPM).

Description:

This is the six-month treatment extension of Study MRS-TU-2019, which like Study MRS-TU-2019 (NCT03198728), is an open-label study. The MRS-TU-2019 ABPM Extension Study (MRS-TU-2019EXT; NCT04467697), will extend the participation for up to 170 MRS-TU-2019 subjects who chose to enroll into the MRS-TU-2019EXT, for a target of 135 evaluable subjects reaching the 4-month ABPM assessment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: May 1, 2020
• Est. primary completion date: May 1, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

For all subjects participating in MRS-TU-2019EXT, whether rolling on from MRS-TU-2019 or newly enrolling, the following MRS-TU-2019EXT Inclusion/Exclusion Criteria apply:

Inclusion Criteria:

1. Completion of MRS-TU-2019 Day 365/ End of Treatment

Exclusion Criteria:

1. Upper arm circumference > 45 cm.

2. Long distance driving or planned driving trip (> 60 mins duration where the subject is doing the driving) during period of wearing ABPM cuff.

3. Expected / known forthcoming change to antihypertensive medication(s) during the MRS-TU-2019 EXT extension study.

4. Cardiac arrhythmias that, in the opinion of the investigator, interfere with the ability of the ABPM recorder to obtain reliable measurements.

5. Use of T implantable pellets since completion of Day 365/EOT visit in MRS-TU- 2019.

For newly enrolling subjects into MRS-TU-2019EXT (naïve to MRS-TU-2019), the applicable Inclusion/Exclusion criteria from the MRS-TU-2019 study, also must be met :

MRS-TU-2019 Key Inclusion Criteria:

1. Male aged 18 to 65 years, inclusive, at the time of providing informed consent to participate in the study.

2. Hypogonadism defined as having 2 consecutive serum total T levels = 281 ng/dL based on a blood sample, drawn at least 3 days apart, between 7 a.m. and 10 a.m.

3. At least 1 clinical feature consistent with male hypogonadism. If a subject is receiving commercial TRT prior to Screening Visit 1, he must have a history of at least 1 clinical feature consistent with male hypogonadism.

4. Must be naïve to androgen replacement therapy or washed out adequately of prior androgen replacement therapies; willing to cease current T treatment; or currently not taking any T treatment. Subjects must remain off all forms of T, except for dispensed study drug, throughout the entire study.

5. No unstable ongoing concomitant medical conditions. Treated and well-controlled conditions such as type 2 diabetes, hypertension, or dyslipidemia are acceptable with stable medication in place for at least 3 months prior to study entry:

1. Hemoglobin A1c < 8.0%

2. BP < 150/90 mm Hg

• *for MRS-TU-2019EXT ABPM Extension Study, the in-clinic, average BP must be < 140/90 for inclusion into the MRS-TU-2019EXT study.

3. Low-density lipoprotein cholesterol < 190 mg/dL.

6. Subjects with an endocrine disorder requiring treatment other than hypogonadism must be on a stable dose of replacement medication for at least 3 months prior to study entry.

7. Adequate venous access to allow collection of a number of blood samples via a venous cannula.

8. Written informed consent to participate in the study and ability to comply with all study requirements.

MRS-TU-2019 Key Exclusion Criteria:

1. Serum PSA > 2.5 ng/ml and/or abnormal prostate gland on palpation, e.g., palpable nodes, at Screening Visit 2.

2. Received oral, topical, intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration within the previous 4 weeks, intramuscular T injection of long-acting duration within the previous 20 weeks, or T implantable pellets within the previous 6 months.

*For ABPM Extension Study Only: Newly Enrolled Subjects to MRS-TU-2019EXT ABPM Extension Study, patients must not have received prior testosterone replacement therapy within 8 weeks of the start of the study, with the exception of T implantable pellets which are excluded for 6 months.

3. Use of any drug that could interfere with measurement or assessment of serum androgen levels, including 5 alpha-reductase inhibitors, anabolic steroids, and drugs with antiandrogenic properties (e.g., spironolactone, cimetidine, flutamide, bicalutamide, and ketoconazole). These drugs must be stopped for at least 1 month prior to study entry (6 months in the case of dutasteride). Patients taking potent, long- acting opiate therapy on a daily basis are not eligible for the study. Conversely, ad hoc use of potent, short-acting opiates for a period of less than 7 days may be permitted after discussion with the Marius Pharmaceuticals medical monitor.

4. Use of over-the-counter products, including natural health products (e.g., food supplements and herbal supplements such as saw palmetto or phytoestrogens) that may affect total T levels, within 7 days prior to study entry.

5. History of drug or alcohol abuse within the past 2 years that in the opinion of the investigator could interfere with study participation and/or influence study efficacy and safety endpoints assessments.

6. Unstable or chronic disease that could interfere with participation in the study or patient safety, including psychiatric disorders.

7. Myocardial infarction, coronary artery surgery, heart failure, stroke, unstable angina, or other unstable cardiovascular disease within the past 6 months.

8. Abnormal ECG considered clinically significant by investigator at Screening.

9. Diagnosis of any cancer within the previous 5 years other than basal or squamous cell skin cancer with clear margins.

10. Any surgical or medical condition that might alter administration of the study drug or comparator, including history of gastric surgery, cholecystectomy, vagotomy, small bowel resection, or any surgical procedure or medications (e.g., GLP-1 agonists and motility agents such as domperidone, metoclopramide, etc.) that might interfere with gastrointestinal motility, pH, or absorption of TU.

11. Duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to screening.

12. Chronic skin conditions on the chest or upper arms that would prevent administration of AndroGel in a manner designed to ensure reliable and consistent absorption thereof

13. Human immunodeficiency virus (HIV) infection.

14. Chronic hepatitis B virus and/or hepatitis C virus (HCV) infection (as determined by positive testing for hepatitis B virus surface antigen or HCV antibody with confirmatory testing, i.e., detectable serum HCV ribonucleic acid [RNA])

15. Clinically significant abnormal laboratory values at screening including but not limited to:

1. Elevated liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT] > 2X upper limit of normal)

2. Estimated glomerular filtration rate < 60 ml/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease formula

3. Hemoglobin < 11.0 g/dL or > 16.0 g/dL. For a subject previously on testosterone replacement therapy with less than 30 days washout prior to screening Visit 2, hemoglobin < 11.0 g/dL or > 17.0 g/dL.

16. Severe or untreated obstructive sleep apnea syndrome.

17. Severe lower urinary tract symptoms (American Urological Association/ IPSS = 19).

18. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study entry.

19. Past, current, or suspected prostate or breast cancer.

20. History of long QT syndrome or unexplained sudden death in a first-degree relative (parent, sibling, or child).

21. Concurrent treatment with medications that may impact the absorption, distribution, metabolism, or excretion of TU or place the subject at risk for treatment with T.

22. Subject has a partner who is currently pregnant or planning pregnancy during the course of the study.

23. Treatment with any other investigational drug within 30 days of study entry or > 5 half- lives (whichever is longer) and at any time during the study.

24. History of noncompliance to medical regimens or potential unreliability in the opinion of the investigator.

25. Unwilling or unable to comply to the dietary requirements for this study.

26. History of polycythemia, either idiopathic or associated with TRT.

27. Donated blood (= 500 mL) within the 12-week period prior to study entry.

28. History of an abnormal bleeding tendency or thrombophlebitis within the previous 2 years that is not linked to venipuncture or intravenous cannulation.

29. Onset of gynecomastia within the previous 6 months.

Related Conditions & MeSH terms

• Hypogonadism
• Hypogonadism, Male

Intervention

Drug:
• SOV2012-F1
oral preparation of testosterone undecanoate (TU)

Locations

Country	Name	City	State
United States	South Florida Medical Research	Aventura	Florida
United States	Urologic Consultant of SE Pennyslvania	Bala-Cynwyd	Pennsylvania
United States	Alabama Clinical Therapeutics, LLC	Birmingham	Alabama
United States	Northwest Clinical Trials	Boise	Idaho
United States	PAB Clinical Research	Brandon	Florida
United States	University Diabetes Endocrine Consultants	Chattanooga	Tennessee
United States	Rapha Institute for Clinical Research	Fayetteville	North Carolina
United States	Accumed Research Associates	Garden City	New York
United States	Centex Studies, Inc.	Houston	Texas
United States	Jacksonville Impotence Treatment Center	Jacksonville	Florida
United States	Centex Studies, Inc.	Lake Charles	Louisiana
United States	Palm Research Center, Inc.	Las Vegas	Nevada
United States	My Community Research Center	Miami	Florida
United States	Coastal Clinic Research Inc	Mobile	Alabama
United States	Coastal Carolina Research Center	Mount Pleasant	South Carolina
United States	Manhattan Medical Research Practice, PLLC	New York	New York
United States	Quality Clinical Research, Inc.	Omaha	Nebraska
United States	Oviedo Medical Research, LLC	Oviedo	Florida
United States	Meridien Research	Saint Petersburg	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Marius Pharmaceuticals	Syneos Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of AEs, SAEs and AEs leading to MRS-TU-2019EXT study withdrawal of SOV2012-F1 treated subjects.	Number of subjects of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study withdrawal in SOV2012-F1-treated subjects	90, 120 and 180 days
Other	Observed and change from baseline in blood pressure (BP) obtained using in-clinic BP measurement during the treatment period.	Measured by in-clinic BP measurement, mm HG	90, 120 and 180 days
Other	Observed and change from baseline in heartrate (HR) obtained using in-clinic HR measurement during the treatment period.	Measured by in-clinic HR measurement, beats per minute	90, 120 and 180 days
Other	Assess observed and change from baseline in hematology parameters in Liver function tests	Alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase in SOV2012-F1 treated subjects during the treatment period measured by laboratory assessment, measured in Units per Liter (U/L)	90 and 180 days
Other	Assess observed and change from baseline in hematology parameters in Liver function tests	Total bilirubin in SOV2012-F1 treated subjects during the treatment period measured by laboratory assessment, measured in mg/dL	90 and 180 days
Other	Assess observed and change from baseline in hematology parameters (hemoglobin) in SOV2012-F1 treated subjects during the treatment period.	Measured by laboratory assessment.	90 and 180 days
Other	Assess observed and change from baseline in hormone levels.	Luteinizing hormone [LH], follicle-stimulating hormone [FSH], dihydrotestosterone [DHT], sex hormone-binding globulin [SHBG], thyroid stimulating hormone [TSH] in SOV2012-F1 treated subjects during the treatment period measured by laboratory assessment.	90 and 180 days
Other	Assess observed and change from baseline in lipid profiles (high and low-density lipoproteins, total cholesterol, triglycerides) in SOV2012-F1 treated subjects during the treatment period.	Measured by laboratory assessment	90 and 180 days
Other	Assess observed and change from baseline in Serum prostate-specific antigen (PSA) in SOV2012-F1 treated subjects during the treatment period.	Measured by laboratory assessment	90 and 180 days
Primary	Change from baseline in 24-hour average ambulatory systolic blood pressure (sBP) after approximately 120 days treatment	Measured by Ambulatory Blood Pressure Monitoring (ABPM)	120 days
Primary	To determine response to a lower starting dose of oral SOV2012-F1 with up and down titration	Percentage of SOV2012-F1-treated subjects with a plasma T Cavg within the normal range after 90 days of treatment. Measured by Plasma T concentration.	90 days
Secondary	Change from baseline in 24-hour average ambulatory systolic blood pressure, using ABPM, after approximately 180 days (+/-3) of treatment.	Measured by Ambulatory Blood Pressure Monitoring (ABPM)	180 days
Secondary	Measuring ambulatory blood pressure by ABPM after 120 days (+/-3) and 180 days (+/-3) of SOV treatment	Measured by Ambulatory Blood Pressure Monitoring (ABPM) at: Change from baseline in 7 AM to 10:30 PM -hour average ambulatory systolic blood pressure (daytime); Change from baseline in 11 PM to 6:30 AM -hour average ambulatory systolic blood pressure (nighttime); Maximum 24-hour systolic ambulatory blood pressure; Change from baseline in 7 AM to 10:30 PM -hour average ambulatory diastolic blood pressure (daytime); Change from baseline in 11 PM to 6:30 AM -hour average ambulatory diastolic blood pressure (nighttime); Change from baseline in 24-hour mean diastolic blood pressure (dBP); Maximum 24-hour diastolic blood pressure	120 and 180 days
Secondary	Measuring ambulatory heart rate by ABPM after 120 days (±3) of SOV treatment, and after 180 days (±3) of SOV treatment.	Measured by Ambulatory Blood Pressure Monitoring (ABPM) at: Change from baseline in 24-hour average ambulatory heartrate; Change from baseline in 7 AM to 10:30 PM -hour average ambulatory heartrate (daytime); Change from baseline in 11 PM to 6:30 AM -hour average ambulatory heartrate (nighttime)	120 and 180 days
Secondary	Observed and change from baseline in half hourly systolic blood pressure and diastolic blood pressure, as measured by ABPM after after 120 days (±3) of SOV treatment, and after 180 days (±3) of SOV treatment.	Measured by Ambulatory Blood Pressure Monitoring (ABPM) in mm HG	120 and 180 days
Secondary	Observed and change from baseline in half hourly heart rate measurement, as measured by ABPM after after 120 days (±3) of SOV treatment, and after 180 days (±3) of SOV treatment.	Measured by Ambulatory Blood Pressure Monitoring (ABPM) in beats per minute	120 and 180 days
Secondary	Percentage of SOV2012-F1-treated subjects with maximum plasma testosterone concentration (T Cmax) values after 90 days of treatment: < 1500 ng/dL; > 1800 to = 2500 ng/dL; > 2500 ng/dL.	Measured by plasma T levels	90 days

External Links

•   MRS-TU-2019 protocol, ClinicalTrials.gov ID: NCT03198728